BC
BMY icon

Birchview Capital’s Bristol-Myers Squibb BMY Stock Holding History

Birchview Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
306,268
+3,426
+1% +$200K 10.57% 2
2025
Q4 		$16.3M Sell
302,842
-14,000
-4% -$674K 9.56% 2
2025
Q3 		$14.3M Sell
316,842
-6,516
-2% -$304K 10.79% 2
2025
Q2 		$15M Sell
323,358
-361,834
-53% -$17.8M 14.86% 1
2025
Q1 		$41.8M Buy
685,192
+10
+0% +$583 36.29% 1
2024
Q4 		$38.8M Sell
685,182
-1,000
-0.1% -$55.9K 31.53% 1
2024
Q3 		$35.5M Sell
686,182
-2,036
-0.3% -$95.5K 30.74% 1
2024
Q2 		$28.6M Sell
688,218
-15,388
-2% -$689K 26.42% 1
2024
Q1 		$38.2M Buy
703,606
+1,308
+0.2% +$66.6K 31.1% 1
2023
Q4 		$36M Sell
702,298
-13,999
-2% -$735K 28.19% 1
2023
Q3 		$41.6M Sell
716,297
-12,288
-2% -$753K 35.32% 1
2023
Q2 		$46.6M Hold
728,585
– – 34.92% 1
2023
Q1 		$50.5M Buy
728,585
+800
+0.1% +$56.4K 39.54% 1
2022
Q4 		$52.4M Hold
727,785
– – 36.99% 1
2022
Q3 		$51.7M Hold
727,785
– – 36.43% 1
2022
Q2 		$56M Sell
727,785
-26,321
-3% -$2M 40.76% 1
2022
Q1 		$55.1M Sell
754,106
-12,000
-2% -$806K 39.65% 1
2021
Q4 		$47.8M Sell
766,106
-30,000
-4% -$1.76M 30.8% 1
2021
Q3 		$47.1M Hold
796,106
– – 32.05% 1
2021
Q2 		$53.2M Buy
796,106
+1,920
+0.2% +$125K 31.82% 1
2021
Q1 		$50.1M Sell
794,186
-200
-0% -$12.4K 29.76% 1
2020
Q4 		$49.3M Hold
794,386
– – 28.39% 1
2020
Q3 		$47.9M Buy
794,386
+2,000
+0.3% +$120K 32% 1
2020
Q2 		$46.6M Buy
792,386
+6,601
+0.8% +$395K 28.16% 1
2020
Q1 		$43.8M Buy
785,785
+7,200
+0.9% +$440K 38.85% 1
2019
Q4 		$50M Buy
778,585
+731,585
+1,557% +$41.9M 36.33% 1
2019
Q3 		$2.38M Buy
47,000
+3,000
+7% +$141K 1.59% 7
2019
Q2 		$2M Buy
44,000
+24,000
+120% +$1.12M 1.21% 8
2019
Q1 		$954K Buy
+20,000
New +$996K 0.6% 16

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Birchview Capital's BMY Position: Q1 2026 in Review

Birchview Capital increased its Bristol-Myers Squibb (BMY) stake by 1.1% in Q1 2026, buying an estimated $200K and bringing the position to 306,268 shares worth $18.6M. The position accounts for 10.57% of the portfolio, ranked #2.

Birchview Capital first reported a position in BMY in Q1 2019 and has held it in 29 quarters since. The position peaked at $56M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Birchview Capital held 306,268 shares of Bristol-Myers Squibb worth $18.6M as of Q1 2026.
  • Birchview Capital bought 3,426 Bristol-Myers Squibb shares in Q1 2026, an estimated $200K.
  • Bristol-Myers Squibb made up 10.57% of Birchview Capital's portfolio in Q1 2026, its #2 holding.
  • Birchview Capital first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 29 quarters since.
  • Birchview Capital's Bristol-Myers Squibb position peaked at $56M in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.